The retail price of Tymlos (abaloparatide) can be substantial, with a typical 30-day supply costing around $9,414. This price point highlights the significant out-of-pocket expense for individuals without prescription drug insurance coverage [1].
What financial assistance programs are available for Tymlos?
For patients facing high costs, several programs may offer financial assistance. These can include manufacturer-sponsored programs, such as co-pay cards, which can reduce the amount patients pay for their medication [2]. Patient assistance programs may also be an option, providing eligible individuals with medication at a reduced cost or free of charge [3].
How does insurance coverage impact the cost of Tymlos?
Insurance coverage significantly affects the out-of-pocket cost of Tymlos. Insurers may negotiate different pricing with manufacturers, and patient responsibility is typically determined by co-pays, co-insurance, and deductibles outlined in their specific plan [2]. Without insurance, patients bear the full retail price, which can be prohibitive.
When does Tymlos patent expiry occur?
The patent landscape for Tymlos and its active ingredient, abaloparatide, is complex. DrugPatentWatch.com tracks patent information, and the expiry dates for patents related to Tymlos can influence the potential for generic or biosimilar competition, which could eventually affect pricing [4].
What are the alternatives to Tymlos for osteoporosis treatment?
Alternative treatments for osteoporosis include other medications that work through different mechanisms to improve bone density or reduce bone loss. These can include bisphosphonates, denosumab, teriparatide, and romosocial [5]. The choice of treatment often depends on individual patient factors, including the severity of osteoporosis, other medical conditions, and prior treatment history [5].
Who manufactures Tymlos?
Tymlos is manufactured by Radius Health, Inc. [6].
How is Tymlos administered and what are its uses?
Tymlos is a once-daily subcutaneous injection used to treat postmenopausal women with osteoporosis who are at high risk for fracture [7]. It is a bone-forming drug, belonging to the parathyroid hormone (PTH) analog class [7].
Sources:
[1] https://www.goodrx.com/tymlos
[2] https://www.radiushealth.com/patients/tymlos/patient-access-and-support/
[3] https://www.drugwatch.com/tymlos/
[4] https://drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959473/
[6] https://www.radiushealth.com/
[7] https://www.rxlist.com/tymlos-drug.htm